Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 01, 2004. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 17, 2004.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed relates to the share buyback transaction:
- Shares Purchased: 895,000 Ordinary shares of 25 pence each.
- Purchase Date: November 30, 2004.
- Purchase Price: 1,110 pence per share.
- Treasury Holdings: 55,778,000 shares held in Treasury following the purchase.
- Shares in Issue: 5,878,090,023 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the acquisition of 895,000 shares for Treasury. The filing text does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 895,000 share repurchase (895,000 shares x 1,110 pence).
- Confirm the updated total share capital and Treasury share count in subsequent filings.
- Review the full Annual Report (Form 20-F) for comprehensive financial performance metrics not included in this 6-K.